Trial Profile
A Prospective, Multi-Center, Single-Arm study of efficacy and safety of apatinib mesylate in the treatment of recurrent and / or metastatic head and neck squamous cell carcinoma with one-line / multi-line chemotherapy failure
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Jun 2019 Preliminary results (data cut-off date: Jan 31, 2019) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 22 Mar 2018 New trial record